首页> 外文期刊>Drug delivery. >Identification and imaging of miR-155 in the early screening of lung cancer by targeted delivery of octreotide-conjugated chitosan-molecular beacon nanoparticles
【24h】

Identification and imaging of miR-155 in the early screening of lung cancer by targeted delivery of octreotide-conjugated chitosan-molecular beacon nanoparticles

机译:通过靶向递送奥曲肽偶联的壳聚糖-分子信标纳米粒子,在肺癌早期筛查中鉴定和成像miR-155

获取原文
           

摘要

Lung cancer is still the most common cancer globally. Early screening remains the key to improve the prognosis of patients. There is currently a lack of specific and sensitive methods for early screening of lung cancer. In recent years, studies have found that microRNA plays an important role in the occurrence and development of lung cancer and become a biological target in the early diagnosis of lung cancer. In this study, lung cancer cells, subcutaneous xenografts of lung cancer in nude mice, and Lox-Stop-lox K-ras G12D transgenic mice were used as models. The transgenic mice displayed the dynamic processes from normal lung tissue to atypical hyperplasia, adenomas, carcinoma in situ and lung adenocarcinoma. It was found that miR-155 and somatostatin receptor 2 (SSTR2) were expressed in all the disease stages of transgenic mice. Through molecular beacon (MB) technology and nanotechnology, chitosan-molecular beacon (CS-MB) nanoparticles and targeted octreotide (OCT) were conjugated and synthesized. The octreotide-conjugated chitosan-molecular beacon nanoparticles (CS-MB-OCT) can specifically bind to SSTR2 expressed by the lung cancer cells to achieve the goal of identification of lung cancer cells and imaging miR-155 in vivo and in vitro. Fluorescence imaging at different disease stages of lung cancer in Lox-Stop-lox K-ras G12D transgenic mice was performed, and could dynamically monitor the occurrence and development of lung cancer by different fluorescence intensity ranges. The current research, in turn, provides new idea, new method, and new technology for the early screening of lung cancer.
机译:肺癌仍然是全球最常见的癌症。早期筛查仍然是改善患者预后的关键。当前缺乏用于早期筛查肺癌的特异性和灵敏方法。近年来,研究发现微小RNA在肺癌的发生和发展中起重要作用,并成为肺癌早期诊断的生物学靶标。在这项研究中,肺癌细胞,裸鼠肺癌皮下异种移植和Lox-Stop-lox K-ras G12D转基因小鼠被用作模型。转基因小鼠表现出从正常肺组织到非典型增生,腺瘤,原位癌和肺腺癌的动态过程。发现在转基因小鼠的所有疾病阶段中都表达了miR-155和生长抑素受体2(SSTR2)。通过分子信标(MB)技术和纳米技术,共轭和合成了壳聚糖分子信标(CS-MB)纳米粒子和目标奥曲肽(OCT)。结合奥曲肽的壳聚糖分子信标纳米粒子(CS-MB-OCT)可以与肺癌细胞表达的SSTR2特异性结合,从而达到鉴定肺癌细胞和在体内外进行miR-155成像的目的。在Lox-Stop-lox K-ras G12D转基因小鼠中进行了肺癌不同疾病阶段的荧光成像,可以通过不同的荧光强度范围动态监测肺癌的发生和发展。反过来,当前的研究为肺癌的早期筛查提供了新思路,新方法和新技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号